Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 1998

View Archived Issues

Dainippon will initiate European development of antipsychotic drug candidate

Dainippon's aldose reductase inhibitor in phase II in Japan; European development now planned

Preparation and pharmaceutical formulations of nimesulide choline salt claimed by Dompe

Korean research institute develops new NMDA receptor antagonists

Agents for schizophrenia from Yoshitomi typified by Y-36074

RPR presents clinical findings with gpIIb/IIIa antagonist; product dropped due to dosing problems

Apotex conducting early studies on oral chelating agents

NeoTect effective in detecting breast cancer in early clinical study

Yamanouchi discloses 5-HT2C receptor agonists with high potency and selectivity

GeneMedicine, Megabios merger will create industry leader in gene-based therapeutics

Shiseido claims pyrrolidines for gastric and peptic ulcers

Vasogen files for protection of patient-specific treatment of GvHD

New serotonergic agents in development at ADIR for CNS disorders

ThromboSol prolongs cryopreservation of rhTPO-stimulated platelets in in vitro study

Pharmacokinetic and therapeutic equivalence of Zelapar and Eldepryl

AxyS reaches research milestones in collaboration with Warner-Lambert

No risk of liver toxicity with entacapone, Orion says

Clinical, preclinical efficacy of Neovastat featured at recent congress

Temodal recommended for approval in E.U.

Clinical testing of nonantibiotic anti-H. pylori agent will begin; development partner sought

Clinical trials of FS069 begin in Japan

New antiasthmatic agent launched in Italy by Zeneca, Chiesi and Recordati

Idec commences clinical trials with PRIMATIZED anti-B7 antibody in psoriasis

Advisory committee decides against recommending approval for new anticoagulant

New synthetic anti-HIV compound resembling NNRTIs in development at Nippon Suisan

Hughes Institute develops potent and selective d4T analogue as anti-HIV candidate

Design and synthesis of new beta-lactams as potent and selective HCMV protease inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...